Biscayne Neurotherapeutics, Inc.
http://biscayneneuro.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biscayne Neurotherapeutics, Inc.
BI Gets Down To Business Early With Trio Of Pacts
The German group’s fibro-inflammatory deal with Kyowa Kirin has come in the same week as a new oncology collaboration with partner 3T and a liver disease alliance with China’s Ribo.
Boehringer Buoyed By Progress Of Oncology Pipeline
Boehringer Ingelheim is enjoying the financial benefits that have come from the strong growth of Jardiance and has upped its R&D spend to advance promising cancer and fibrosis assets.
Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Biscayne Neurotherapeutics Australia Pty, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice